Business
CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada
CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario,
About this update from Csl Limited
CSL Canada is proud to recognize this important milestone of the first Canadian patient to receive HEMGENIX® (etranacogene dezaparvovec), the one-time gene therapy treatment for eligible patients living with hemophilia B, at London Health Sciences Centre in London, Ontario.Following a successful pan-Canadian Pharmaceutical Alliance (pCPA) agreement, HEMGENIX® is now publicly reimbursed in Ontario and British Columbia via the Exceptional Access Program, with additional provinces under consideration.It is indicated for the treatment of adults (aged 18 years of age or older) with severe to moderately severe hemophilia B (congenital Factor IX deficiency) who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.1 There is no clinical experience of HEMGENIX® use in patients with mild or moderate hemophilia B (FIX activity > 2%).This milestone marks the first HEMGENIX® treatment administered to a Canadian patient outside of a clinical trial, demonstrating real‑world access to gene therapy in Canada. OTTAWA, ON, May 20, 2026 /CNW/ - CSL Canada is proud to announce the first Canadian patient has received HEMGENIX® (etranacogene dezaparvovec), a one-time hemophilia B gene therapy, at London Health Sciences Centre (LHSC). This milestone marks a significant advancement in hemophilia B care, reflecting how clinical innovation and health system collaboration are enabling real-world access to gene therapy for eligible patients in Canada.Hemophilia B is a rare genetic bleeding disorder caused by a deficiency of clotting Factor IX, which prevents blood from clotting properly, often resulting in a lifelong dependence on medication to manage bleeding.2 People living with hemophilia B may experience spontaneous or prolonged bleeding episodes that can lead to joint damage, chronic pain, reduced mobility, and other long-term complications that affect quality of life.3For many patients and families, hemophilia B often means navigating constant vigilance around physical activity, injury risk, and disease management affecting all facets of everyday life. In Canada, hemophilia B affects approximately one in 50,000 people,4 typically requiring lifelong management through medical monitoring, specialized multidisciplinary care and sustained healthcare system resources through hemophilia treatment centres.5HEMGENIX® is a gene therapy ...